Impact of Photopheresis in the Prevention of Acute Rejection in Highly Sensitized de Novo Kidney Transplant Recipients
Not Applicable
Recruiting
- Conditions
- Kidney Transplant Rejection
- Registration Number
- NCT04414735
- Lead Sponsor
- Fundacion Clinic per a la Recerca Biomédica
- Brief Summary
The aim of the present study is to evaluate the superiority of photopheresis in combination with the standard immunosuppression vs standard immunosuppression alone for the prevention of acute rejection in highly sensitized kidney transplant recipients (cPRA ≥90%).
Unicentric, randomized, open study.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- Sensitized (cPRA ≥90%) candidates for a deceased-donor kidney transplantation
- Recipients between 18 and 75 years old
- Patients are able to understand and sign informed consent (Annex 1).
Exclusion Criteria
- Participation in another interventional clinical trial.
- Use of Rituximab or Eculizumab at the time of transplant or in the first 24 hours post-transplant.
- Persons with any dependency on the researcher or employee by the responsible institution or researcher. As well as people detained by legal order.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Time to first histological rejection in the first year of kidney transplantation. 1 year after kidney transplantation Time to first histological rejection in the first year of kidney transplantation.
- Secondary Outcome Measures
Name Time Method Biopsy proved acute rejection 1 year after kidney transplantation Glomerular filtrate rate at one year after kidney transplant 1 year after kidney transplantation
Trial Locations
- Locations (1)
Deparment of Nephology and Kidney Transplant
🇪🇸Barcelona, Please Select, Spain
Deparment of Nephology and Kidney Transplant🇪🇸Barcelona, Please Select, SpainGastón J Piñeiro, MDSub InvestigatorFritz Diekmann, MD, PhDContact+34932275400fdiekman@clinic.catFritz Diekmann, MD,PhDPrincipal InvestigatorJordi Rovira, PhDSub InvestigatorPedro Ventura, MD, PhDSub Investigator
